|Summary sheet: Kratom|
|Common names||Mitragyna Speciosa, กระท่อม (Thai), Ketum, Kratom, Kratum|
|Psychoactive class||Opioid / Stimulant|
|Chemical class||Indole alkaloids|
|Routes of Administration|
Mitragyna speciosa (also known as kratom) is a tropical tree of the coffee family indigenous to South East Asia. The leaves of M. speciosa contain various psychoactive alkaloids that produce mild stimulant and opioid effects. The pharmacology of kratom is complex, although it produces its major effects through action at opioid receptors in the brain.
M. speciosa is indigenous to Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea, where it has been used in traditional medicines for centuries. Traditionally, fresh or dried kratom leaves are chewed or made into tea. Starting in the 2000s, kratom began to receive significant attention due to increased use in Western cultures as an alternative medicine. It is readily available for purchase from a large number of internet vendors, most commonly in the form of dried and powdered leaves.
Subjective effects include sedation, stimulation, pain relief, anxiety suppression, muscle relaxation, and euphoria. Like cannabis, users report that the effects of kratom can vary depending on the dose and strain. Lower doses are generally reported to produce caffeine-like stimulant effects such as enhanced focus and motivation while higher doses produce typical opioid effects like pain relief, sedation, and euphoria. Many users claim kratom is useful in treating opioid addiction as a weaning agent, particularly during the initial withdrawal phase. Kratom exists in a variety of strains with different characteristics, some more opioid-like than others.
Kratom’s mood-elevating effects have raised concerns about the plant’s potential for dependence and abuse. In some jurisdictions, its sale and importation have been restricted, and several public health authorities have raised alerts. Additionally, strong evidence for many of the claimed benefits promoted by kratom vendors and communities are currently lacking. It is highly advised to use harm reduction practices if using this substance.
The leaves of M. speciosa contain more than 40 compounds, including many indole alkaloids such as mitragynine, mitraphylline, and 7-hydroxymitragynine (which is currently the most likely candidate for the primary active chemical in the plant). Other active compounds in M. speciosa include raubasine, rhynchophylline, and corynantheidine, among many others.
The amount of active alkaloids in the leaves highly depends on many factors. One major factor is the location of the tree. When trees are grown in Southeast Asia, the levels tend to be higher but when grown elsewhere (even in greenhouses) the levels tend to be low or non-existent. One analysis of products marketed as kratom leaf found mitragynine at levels of 1–6% and 7-hydroxymitragynine at levels of 0.01–0.04%.
The plant's active compounds and metabolites are not detected by a typical drug screening test, but can be detected by more specialized testing. Blood mitragynine concentrations are expected to be in a range of 10–50 μg/L in persons using the drug recreationally. Detection in body fluids is typically by liquid chromatography-mass spectrometry.
Kratom behaves as an opioid receptor agonist similar in function to morphine and other opiates, although its pharmacological action and subjective effects differ significantly from those of traditional opiates.
Opioids exert their effects by binding to and activating the opioid receptors. They structurally mimic endogenous endorphins which are naturally found within the body and also work upon the opioid receptor system. The way in which opioids structurally mimic these natural endorphins results in their euphoric, pain-relieving and anxiolytic effects. This is because endorphins are responsible for reducing pain, causing sedation, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement.
Mitragynine and 7-hydroxymitragynine bind as partial agonists to the μ-opioid receptors and antagonistic to the κ- and δ-opioid receptors. They have high binding affinities to the µ- and κ-receptors. The binding affinity to the δ-receptors is high for 7-hydroxymitragynine, but weak for mitragynine.
Unlike most other opioids, kratom also presents affinity for the norepinephrine and serotonin receptor systems where it functions as an agonist. Its action on norepinephrine and serotonin also likely contributes to kratom's stimulating properties.
Additionally, kratom contains the alkaloid rhynchophylline, which functions as an NMDA receptor antagonist. This may be responsible for the mild dissociating effects which occur at heavy doses.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Stimulation & Sedation - Kratom can act as both a stimulant and a sedative depending on the strain and dose. The sedating and stimulating effects may occur simultaneously in a contradictory manner resulting in the sensation that one is both energized and relaxed. These may also occur at different times during the experience; a person may feel stimulated during the come up and sedated during the come down. Kratom is considerably more stimulating than that of traditional opioids including oxycodone, heroin, and codeine.
- Physical euphoria - Kratom reliably produces physical euphoria at higher doses. However, this euphoria is not as intense as the euphoria of opioids like heroin, or oxycodone. The sensation itself can be described as moderate feelings of intense physical comfort, warmth, love and contentment.
- Pain relief - Kratom can produce pronounced pain relief, with some users reporting that high doses of kratom produce analgesic effects equivalent to over 20 mg of hydrocodone (commonly known as "Vicodin").
- Cough suppression
- Nausea - with strong doses or frequent re-dosing, one may feel quite ill and the nausea can last upwards of two days at the worst. For this reason, a light and healthy diet is recommended in the days prior to consuming higher doses of kratom.
- Increased perspiration
- Stomach cramps
- Appetite suppression
- Body odor alteration - Kratom can cause one's urine to acquire a very distinct and unpleasant odor for a subset of users.
- Decreased libido
- Difficulty urinating
- Orgasm suppression
- Pupil constriction
- Visual disconnection - A sense of subtle disconnection from visual input is often experienced with high doses of kratom. This is similar to a low-level version of the same effect universally experienced with dissociatives and may be a result of NMDA antagonist properties of rhynchophylline, an alkaloid found in kratom.
The cognitive effects of kratom can be broken down into several components which progressively intensify proportional to dosage.
The most prominent of these cognitive effects generally include:
- Anxiety suppression
- Cognitive euphoria - In comparison to other opioids, kratom can be considered as less intense in its cognitive euphoria when compared with that of morphine or heroin.
- Dream potentiation
- Increased music appreciation
- Focus enhancement - Focus enhancement occurs at lower doses and disappears as the dose is increased and the sedative and euphoric effects take over.
- Motivation enhancement
- Sleepiness - Certain strains of kratom are noted to sometimes make users very tired. In high dosages this can get to the point where the user may be drifting in and out of consciousness or even experience what is called "nodding".
- Thought acceleration
The visual effects of kratom are pronounced compared to other opioids of its class. They can be broken down into several components which progressively intensify proportional to dosage.
- Internal hallucination - The internal hallucinations of kratom can be described as more solid than psychedelics and do not seem to be composed of visual geometry. They typically manifest themselves through hypnagogic scenarios. They are most common with high doses and can be comprehensively described in their variations as lucid in believability, fixed in style, autonomous in controllability, and equal in new experiences and memory replays in content.
Anecdotal reports which describe the effects of this compound within our experience index include:
- Experience:6-10g Red Maeng Da - Minor Dissociation and a Peculiar "Nod"
- Experience:Kratom + Phenibut + Cannabis - Warm Bliss
- Experience:Red Borneo Kratom (4.2g)
- Experience:~6000mg DXM Freebase + 4g's Red Vein Kratom + HHC + Nitrous - Five Days of Disassociation
Additional experience reports can be found here:
There is a popular belief of kratom being similar to cannabis, where there are many different strains of Mitragyna speciosa available from vendors. The strains are thought to be named and identified after the country/region where the Mitragyna speciosa tree originated as well as the color of the veins of the leaf, but there isn't any proof supporting that theory.
Another popular theory, supported by a report from a visit to Indonesia Kratom farms , say that once harvested, fresh leaves are dried, and depending of the procedure followed, they will be used to make different types of kratom. Once leaves are dry, they crumble them and have the skeleton of the leaf left behind, which they call bones. We call them veins. Veins/bones are not mixed up into most vendors powder except for the small amount used in white. That said, some vendors will add a small amount of bones to all their product, again it depends on their preference. In general, bones are discarded with the exception of the small amount put into white. Bones are allegedly stimulating.
- Red Vein: Fresh leaves are taken and fermented in plastic bags for 3 days pending outside humidity and temperature and vendors preference. Then they are laid out to dry. Some vendors dry indoor, some dry outdoor.
- Gold/Yellow Vein: These are done similar to red, but only ferment for 2 days rather than 3, then air dried. Yellow typically has white mixed in to finish it off.
- Green Vein: Basic green powder comes from air drying fresh leaves.
- White Vein: White is a mix of green and red, which creates a basic white. Then, they add 'bones' to the mix which helps create the whiter/beige color.
Those veins have varying degrees of depressant, stimulating, and opioid characteristics, most people agree that:
- Red Vein: Red vein kratom is sedating and relaxing, making it better suited for managing insomnia or pain.
- Gold/Yellow Vein: Yellow vein kratom is said to have a variety of effects depending on the vendor, ranging from being almost as sedating as a red vein, to being between green and white veins.
- Green Vein: Green vein effects are a mix between white and red. They are not as stimulating as white vein nor as sedating as red vein.
- White Vein: Leaves with a white vein are reported to be energetic and stimulating, promoting alertness, motivation, and wakefulness in low to moderate doses.
Note that the effects vary across all strains and that the effects are dependent on the dose taken. Not all white strains, for example, will produce the same effects and each strain may work differently in one individual than it does on another.
Unlike popular belief, strains are not individual tree species. They are actually blends. Each strain name has a trade-specific recipe that they're supposed to follow. They are blends of the colors that they have. Any strain is just a blend of the colors that they created from the original green leaves. Each vendor might use different ratio blends, and each vendor might dry them differently like indoor vs outdoor, or for different lengths of time. So there's still a decent amount of room to make one vendor better than the other.
There is also an special kind of vein, called Super Green Vein, which consists in unadulterated green leaves from a tree that has not been over saturated from their wet monsoon season. Hence their super vibrant color. And with this leaf, of course, some vendors make super red by following the red procedures, or even white etc. So, 'super Malay' would be using super green leaves but mixing to the 'Malay' recipe.
Most of the people in Indonesia use plain green or super green.
Consumption and preparation
There are several different ways that kratom is typically ingested:
- Traditionally, kratom users in Thailand would commonly chew whole kratom leaves in order to achieve its stimulating and pain-relieving effects while performing manual labor. However, the amount of leaves needed to be chewed to induce optimal effects is quite high. In addition, kratom leaves are very bitter and few users would find this method bearable.
- Kratom tea is one popular method of consumption. Powdered or crushed kratom leaves are steeped in hot water to extract the alkaloids. Many users choose to place the leaf matter directly into the water without using a tea bag as it ensures that no alkaloids are wasted. Kratom tea is very bitter, so flavorings like honey, peppermint oil, or lemon juice can be added to mask the bitterness.
- Toss and wash is done by placing kratom powder in the back of the mouth, avoiding contact with the taste buds as much as possible, and washing the powder down with a drink. A sweet or acidic drink is typically used to mask the bitter taste of the kratom. Since kratom powder is relatively hydrophobic, it will not always be washed down entirely with the liquid, which can leave a bitter taste and residual kratom powder in the back of the mouth. This can cause coughing or choking if not done correctly, although most people can perform this without any issues.
- Mixing with olive oil is a method that some users have found particularly helpful using powdered kratom. Kratom dissolves very easily in olive oil, and the lipids in the oil suppress the bitter taste of the kratom. Due to the fact that this method dissolves the majority of the powder, the chances of accidentally inhaling the powder or having it get stuck in the throat are minimal.
- Placing kratom in gelatin capsules is a tested ingestion method for avoiding the bitter and unpleasant taste of kratom. Typically, "00" size gelatin or vegetable capsules are filled with kratom powder. This is normally done using a capsule making machine so that many capsules can be filled at once. This also makes it easier to pack the powder down into the capsules, allowing around 0.5 grams of powder in each capsule. Some users dislike having to swallow a large amount of capsules when dosing, but this is an effective method for users who cannot tolerate kratom's bitter taste.
- Extracting kratom is done to reduce the amount of powder one must ingest to feel the effects of kratom. A safe, multisolvent kratom extract recipe can be found at the multisolvent heatless extraction of Kratom tutorial. This extraction reduces the amount of kratom needed to cause the desired effects and can reduce the dosage needed immensely. After drying, the extract can be placed in gelatin capsules on its own or mixed with raw kratom to create a full blend of effects. This is particularly helpful in opiate withdrawal.
Smoking, vaporizing, or insufflating kratom is not seen as a viable means of administration, as the amount of alkaloids needed to produce effects would only be obtained by smoking or snorting an excessive amount of leaf material. In addition, certain kratom alkaloids may be destroyed during the process of combustion.
The effects of kratom can be potentiated using the techniques below.
- Antacids - Taking up to four 750mg antacid tablets approximately 30 - 60 minutes before dosing kratom can increase the intensity of its effects. This works because antacids raise the pH level in the stomach, which increases the absorption of kratom.
- Turmeric / Curcumin and Black pepper - A tablespoon or 7 grams of turmeric and a large pinch of black pepper will greatly increase the potency of kratom as well as lengthen its duration if taken approximately 1 hour before ingestion. This works because turmeric functions as an MAOI. Although turmeric is mostly inactive by itself, black pepper increases its bioavailability by 2000% percent.
- Grapefruit juice - Drinking a large glass of grapefruit juice approximately 2 hours before ingesting kratom can greatly potentiate its intensity. This works because grapefruit juice functions as a CYP3A4 enzyme inhibitor which results in altered drug metabolism.
- DXM - Taking 30 - 60 mg of DXM approximately 45 - 60 minutes before ingesting kratom is said to potentiate its effects.
- Watercress - Ingesting watercress approximately 45 minutes before kratom is said to potentiate its effects. This works because watercress functions as a cytochrome P450 CYP2E1 enzyme inhibitor which results in altered drug metabolism.
- Agmatine - Ingesting agmatine on an empty stomach alongside kratom potentiates its opioid receptor mediated pain relief while preventing development of tolerance.
Preparation methods for this compound within our tutorial index include:
Toxicity and harm potential
Kratom has a low toxicity relative to dose. Like most opioids, safe usage of kratom is not known to cause any dangerous long-term complications. Heavy dosages of kratom can result in increased respiratory depression, leading onto fatal or dangerous levels of anoxia (oxygen deprivation). This is significantly less powerful than the respiratory depression of heroin or morphine. This occurs because the breathing reflex is suppressed by agonism of µ-opioid receptors proportional to the dosage consumed.
It is likely impossible to achieve this using kratom in its standard leaf form as the nausea ceiling makes it difficult to consume high enough dosages without vomiting. A pure extract or tincture, however, may be potent enough to cause lethal respiratory depression at appropriate dosages, although oral administration of pure mitragynine to mice in dosages up to 920 mg/kg did not produce lethal respiratory depression. However, kratom can be fatal when it is combined with other depressants such as alcohol or benzodiazepines.
Side effects associated with chronic kratom use include loss of appetite and weight loss, constipation, decreased libido, apathy, and darkening of the skin color of the face. Chronic use has been associated with bowel obstruction.
It is strongly recommended that one use harm reduction practices when using this substance.
The lethal dosage of kratom is unknown but thought to be far above the active dosage. The precise dosage likely depends on a variety of factors including strain, potency, tolerance and method of consumption. It is unlikely that one could ingest a lethal dosage of kratom powder as the nausea will force one to vomit at around 8 - 9 grams; however, it could be possible to ingest a lethal dosage of a kratom if purer forms such as a resin or pure alkaloids are used.
Three case reports document deaths involving kratom. Other drugs were used in all cases, and in one, kratom was speculated to possibly be the primary cause of death. O-Desmethyltramadol (ODSMT) was present in the latter case, and has been found to be a frequent additive in certain commercial brands of kratom, there were nine cases of death reported in Sweden in 2010 and 2011 relating to use of Krypton, which was kratom mixed with O-Desmethyltramadol.
Dependence and abuse potential
As with other opioids, the kratom produces dependence with chronic use and has a high abuse potential. When dependence has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.
Tolerance to many of the effects of kratom develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Kratom presents cross-tolerance with all other opioids, meaning that after the consumption of kratom all opioids will have a reduced effect.
Chronic kratom use may lead to tolerance to the effects of serotonergic psychedelics due to kratom's antagonism of the 5-HT2A receptor and said receptor's paradoxical down-regulation in response to inhibitors.
Since kratom is classified as an herbal supplement and remains legal in many states, a subset of individuals mistakenly assume that it can be used regularly and eventually discontinued without any withdrawal symptoms. In reality, most individuals who use kratom on a regular basis will experience some withdrawal symptoms following cessation. 
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Alcohol - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely
- Amphetamines - Stimulants increase respiration rate which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.
- Benzodiazepines - Central nervous system and/or respiratory-depressant effects may be additively or synergistically present. The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position blackouts/memory loss likely.
- Cocaine - Stimulants increase respiration rate, which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
- DXM - Generally considered to be toxic. CNS depression, difficulty breathing, heart issues, and liver toxicity have been observed. Additionally if one takes DXM, their tolerance of opiates goes down slightly, thus causing additional synergistic effects.
- GHB/GBL - The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position
- Ketamine - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
- MAOIs - Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.
- MXE - MXE can potentiate the effects of opioids but also increases the risk of respiratory depression and organ toxicity.
- Nitrous - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are common.
- PCP - PCP may reduce opioid tolerance, increasing the risk of overdose.
- Tramadol - Increased risk of seizures. Tramadol itself is known to induce seizures and it may have additive effects on seizure threshold with other opioids. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present.
- Grapefruit - While grapefruit is not psychoactive, it may affect the metabolism of certain opioids. Tramadol, oxycodone, and fentanyl are all primarily metabolized by the enzyme CYP3A4, which is potently inhibited by grapefruit juice. This may cause the drug to take longer to clear from the body. it may increase toxicity with repeated doses. Methadone may also be affected. Codeine and hydrocodone are metabolized by CYP2D6. People who are on medicines that inhibit CYP2D6, or that lack the enzyme due to a genetic mutation will not respond to codeine as it can not be metabolized into its active product: morphine.
- Australia: As of January 2015, kratom is a controlled and prohibited narcotic substance which requires a permit and license to import into the country.
- Canada: As of October 2016, it is illegal to market kratom for any use in which it is ingested. However, kratom may be marketed for other uses, such as incense.
- Europe: As of September 2011, kratom, mitragynine, and 7-hydroxymitragynine are controlled substances in a number of EU Member States such as Denmark, Latvia, Lithuania, Poland, Romania and Sweden.
- Germany: Kratom is not a controlled substance under the BtMG. It is legal, as long as it is not sold for human consumption, according to §2 AMG. This legal opinion was approved by court descision of the OLG Köln (Higher Regional Court Cologne), as of September 11, 2015.
- Japan: Kratom and its active constituents mitragynine and 7-hydroxymitragynine are controlled substances in Japan effective March 9th, 2016.
- Latvia: Kratom and its primary active constituent mitragynine are Schedule I controlled substances according to an amendment on August 16th, 2012.
- Malaysia: The use of kratom leaves is prohibited in Malaysia under Section 30 (3) Poisons Act 1952, and the user may be, penalized with a maximum compound of MYR 10,000 (USD 3,150) or up to 4 years imprisonment.
- New Zealand: Kratom and its primary active constituent mitragynine, after an amendment on August 6, 2015, are Schedule I controlled substances under Medicines Regulations 1984
- Switzerland: Mitragynine and 7-Hydroxymitragynine are controlled substances specifically named under Verzeichnis A.
- Thailand: Possession of kratom leaves is illegal in Thailand, despite the tree being native to the country. The Thai government passed the kratom Act 2486 which made planting the tree illegal and requires existing trees to be cut down. As of October 2, 2013, the justice ministry of Thailand suggested removal of kratom from the narcotic drug list relating to Category 5 of the Narcotic Drug Law of 1979, though still recommended regulating kratom in other ways.
- Turkey: Kratom is a classed as drug and is illegal to possess, produce, supply, or import.
- United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- United States: On August 31, 2016, the DEA issued a statement indicating its intention to place kratom on Schedule I of the U.S. Controlled Substances Act in the temporary scheduling category. This ban would have come into effect on September 30th, 2016, but was withdrawn on October 13th, 2016. A public comment period, which closed on December 1st, 2016. Following the comment period, the DEA will have to issue a new statement of intent to place kratom in Schedule I. While there are states that have pledged to not pursue legislation to ban kratom, many others have passed or have pending legislation to ban kratom. It is currently prohibited in the states of Tennessee, Rhode Island, Vermont, Arkansas, Indiana, and Wisconsin.
- Netherlands: Kratom is legal to possess, buy, and sell in the Netherlands according to the Opium Act of May 12th, 1928.
- ↑ 1.0 1.1 1.2 1.3 Kruegel, A. C., Grundmann, O. (May 2018). "The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse". Neuropharmacology. 134: 108–120. doi:10.1016/j.neuropharm.2017.08.026. ISSN 0028-3908.
- ↑ Rech, M. A., Donahey, E., Cappiello Dziedzic, J. M., Oh, L., Greenhalgh, E. (February 2015). "New Drugs of Abuse". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 35 (2): 189–197. doi:10.1002/phar.1522. ISSN 0277-0008.
- ↑ Commissioner, O. of the (2020), Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse, retrieved 6 February 2018
- ↑ DEA Announces Intent To Schedule Kratom, DEA, 2016, retrieved 31 August 2016
- ↑ 5.0 5.1 Adkins, J. E., Boyer, E. W., McCurdy, C. R. (2011). "Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity". Current Topics in Medicinal Chemistry. 11 (9): 1165–1175. doi:10.2174/156802611795371305. ISSN 1873-4294.
- ↑ Chittrakarn, S., Keawpradub, N., Sawangjaroen, K., Kansenalak, S., Janchawee, B. (16 June 2010). "The neuromuscular blockade produced by pure alkaloid, mitragynine and methanol extract of kratom leaves (Mitragyna speciosa Korth.)". Journal of Ethnopharmacology. 129 (3): 344–349. doi:10.1016/j.jep.2010.03.035. ISSN 0378-8741.
- ↑ Prozialeck, W. C., Jivan, J. K., Andurkar, S. V. (December 2012). "Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects". The Journal of the American Osteopathic Association. 112 (12): 792–799. ISSN 1945-1997.
- ↑ Takayama, H., Ishikawa, H., Kurihara, M., Kitajima, M., Aimi, N., Ponglux, D., Koyama, F., Matsumoto, K., Moriyama, T., Yamamoto, L. T., Watanabe, K., Murayama, T., Horie, S. (25 April 2002). "Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands". Journal of Medicinal Chemistry. 45 (9): 1949–1956. doi:10.1021/jm010576e. ISSN 0022-2623.
- ↑ 9.0 9.1 Ward, J., Rosenbaum, C., Hernon, C., McCurdy, C. R., Boyer, E. W. (1 December 2011). "Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy?". CNS drugs. 25 (12): 999–1007. doi:10.2165/11596830-000000000-00000. ISSN 1179-1934.
- ↑ Kikura-Hanajiri, Ruri; Kawamura, Maiko; Maruyama, Takuro; Kitajima, Mariko; Takayama, Hiromitsu; Goda, Yukihiro (July 2009). "Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant "kratom" (Mitragyna speciosa) by LC-ESI-MS". Forensic Toxicology. 27 (2): 67–74. doi:10.1007/s11419-009-0070-5. ISSN 1860-8973.
- ↑ Baselt, R. C. (2014). Disposition of toxic drugs and chemicals in man (Tenth edition ed.). Biomedical Publications. ISBN 9780962652394.
- ↑ Matsumoto, Kenjiro; Takayama, Hiromitsu; Ishikawa, Hayato; Aimi, Norio; Ponglux, Dhavadee; Watanabe, Kazuo; Horie, Syunji (2006). "Partial agonistic effect of 9-hydroxycorynantheidine on μ-opioid receptor in the guinea-pig ileum". Life Sciences. 78 (19): 2265–2271. doi:10.1016/j.lfs.2005.09.030. ISSN 0024-3205.
- ↑ Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., Sames, D. (1 June 2016). "Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators". Journal of the American Chemical Society. 138 (21): 6754–6764. doi:10.1021/jacs.6b00360. ISSN 0002-7863.
- ↑ Matsumoto, Kinzo; Mizowaki, Maho; Suchitra, Thongpradichote; Murakami, Yukihisa; Takayama, Hiromitsu; Sakai, Shin-ichiro; Aimi, Norio; Watanabe, Hiroshi (1996). "Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems". European Journal of Pharmacology. 317 (1): 75–81. doi:10.1016/S0014-2999(96)00714-5. ISSN 0014-2999.
- ↑ Kang, T.-H., Murakami, Y., Matsumoto, K., Takayama, H., Kitajima, M., Aimi, N., Watanabe, H. (22 November 2002). "Rhynchophylline and isorhynchophylline inhibit NMDA receptors expressed in Xenopus oocytes". European Journal of Pharmacology. 455 (1): 27–34. doi:10.1016/s0014-2999(02)02581-5. ISSN 0014-2999.
- ↑ JohnnyAuesome (2020), The Truth On Strains and Production Personally Witnessed
- ↑ http://kratomsources.com/2011/01/23/10-ways-how-to-take-kratom/
- ↑ 18.0 18.1 18.2 How To Make Kratom Stronger: Kratom Potentiators | http://www.politiquessociales.net/how-to-make-kratom-stronger-kratom-potentiators/
- ↑ Bailey, D. G., Malcolm, J., Arnold, O., David Spence, J. (August 1998). "Grapefruit juice–drug interactions". British Journal of Clinical Pharmacology. 46 (2): 101–110. doi:10.1046/j.1365-2125.1998.00764.x. ISSN 0306-5251.
- ↑ Leclercq, I., Desager, J. P., Horsmans, Y. (August 1998). "Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress". Clinical Pharmacology and Therapeutics. 64 (2): 144–149. doi:10.1016/S0009-9236(98)90147-3. ISSN 0009-9236.
- ↑ Kolesnikov, Y., Jain, S., Pasternak, G. W. (January 1996). "Modulation of opioid analgesia by agmatine". European Journal of Pharmacology. 296 (1): 17–22. doi:10.1016/0014-2999(95)00669-9. ISSN 0014-2999.
- ↑ Su, R.-B., Li, J., Qin, B.-Y. (July 2003). "A biphasic opioid function modulator: agmatine". Acta Pharmacologica Sinica. 24 (7): 631–636. ISSN 1671-4083.
- ↑ Raffa, R. B. (29 October 2014). Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source. CRC Press. ISBN 9781482225198.
- ↑ Hassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H. M., Suhaimi, F. W., Vadivelu, R., Vicknasingam, B. K., Amato, D., Hörsten, S. von, Ismail, N. I. W., Jayabalan, N., Hazim, A. I., Mansor, S. M., Müller, C. P. (February 2013). "From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction". Neuroscience and Biobehavioral Reviews. 37 (2): 138–151. doi:10.1016/j.neubiorev.2012.11.012. ISSN 1873-7528.
- ↑ Neerman, M. F., Frost, R. E., Deking, J. (January 2013). "A drug fatality involving Kratom". Journal of Forensic Sciences. 58 Suppl 1: S278–279. doi:10.1111/1556-4029.12009. ISSN 1556-4029.
- ↑ Holler, J. M., Vorce, S. P., McDonough-Bender, P. C., Magluilo, J., Solomon, C. J., Levine, B. (January 2011). "A drug toxicity death involving propylhexedrine and mitragynine". Journal of Analytical Toxicology. 35 (1): 54–59. doi:10.1093/anatox/35.1.54. ISSN 1945-2403.
- ↑ Kronstrand, R., Roman, M., Thelander, G., Eriksson, A. (May 2011). "Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton". Journal of Analytical Toxicology. 35 (4): 242–247. doi:10.1093/anatox/35.4.242. ISSN 1945-2403.
- ↑ Rosenbaum CD, Carreiro SP, Babu KM (2012). "Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines". Journal of Medical Toxicology. 8 (1): 15–32. doi:10.1007/s13181-011-0202-2. PMC 3550220 . PMID 22271566.
- ↑ Rosenbaum, C. D., Carreiro, S. P., Babu, K. M. (March 2012). "Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines". Journal of Medical Toxicology. 8 (1): 15–32. doi:10.1007/s13181-011-0202-2. ISSN 1556-9039.
- ↑ Warner, M. L., Kaufman, N. C., Grundmann, O. (January 2016). "The pharmacology and toxicology of kratom: from traditional herb to drug of abuse". International Journal of Legal Medicine. 130 (1): 127–138. doi:10.1007/s00414-015-1279-y. ISSN 0937-9827.
- ↑ Van Oekelen, D., Luyten, W. H. M. L., Leysen, J. E. (April 2003). "5-HT2A and 5-HT2C receptors and their atypical regulation properties". Life Sciences. 72 (22): 2429–2449. doi:10.1016/S0024-3205(03)00141-3. ISSN 0024-3205.
- ↑ Kratom Withdrawal Symptoms, 2017
- ↑ 33.0 33.1 Ershad, M., Cruz, M. D., Mostafa, A., Mckeever, R., Vearrier, D., Greenberg, M. I. (March 2020). "Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance". Journal of Addiction Medicine. 14 (2): 172–174. doi:10.1097/ADM.0000000000000535. ISSN 1932-0620.
- ↑ Kratom Legality Map, 2015
- ↑ List of Prohibited Substances in Australia, 2022
- ↑ After U.S. delayed decision on kratom, a look at Canada’s laws on the psychadelic plant
- ↑ http://www.emcdda.europa.eu/publications/drug-profiles/kratom#control
- ↑ Anlage I BtMG - Einzelnorm
- ↑ § 2 AMG - Einzelnorm
- ↑ https://openjur.de/u/866755.html
- ↑ 危険ドラッグの成分５物質及び１植物種を新たに指定薬物に指定, 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)], retrieved 2 May 2022
- ↑ Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
- ↑ "Utusan Malaysia: Pinda akta daun ketum kepada Akta Dadah Berbahaya | http://translate.google.com/translate?hl=en&sl=auto&tl=en&prev=_dd&u=http%3A%2F%2Fwww.utusan.com.my%2Futusan%2FParlimen%2F20121213%2Fpa_02%2FPinda-akta-daun-ketum-kepada-Akta-Dadah-Berbahaya
- ↑ Medicines Regulations 1984 (SR 1984/143) (as at 01 July 2022) Schedule 1 Prescription, restricted, and pharmacy-only medicines – New Zealand Legislation
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- ↑ Kratom in Thailand: Decriminalization and Community Control? | http://www.tni.org/sites/www.tni.org/files/download/kratom-briefing-dlr13.pdf
- ↑ hBaşbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü
- ↑ https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf
- ↑ Psychoactive Substances Act 2016
- ↑ Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine into Schedule I (Drug Enforcement Agency) | https://s3.amazonaws.com/public-inspection.federalregister.gov/2016-20803.pdf
- ↑ Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7-Hydroxymitragynine Into Schedule I, 2016
- ↑ Indiana HB1196, 2012, Regular Session
- ↑ Koninkrijksrelaties, M. van B. Z. en, Opiumwet